MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis.
Saved in:
| Title: | MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. |
|---|---|
| Authors: | Spec, Andrej1 (AUTHOR) andrejspec@wustl.edu, Pullman, John2 (AUTHOR), Thompson, George R3 (AUTHOR), Powderly, William G1 (AUTHOR), Tobin, Ellis H4 (AUTHOR), Vazquez, Jose5 (AUTHOR), Wring, Stephen A6 (AUTHOR), Angulo, David6 (AUTHOR), Helou, Silvia6 (AUTHOR), Pappas, Peter G7 (AUTHOR), Group, Mycoses Study (AUTHOR), Mycoses Study Group (CORPORATE AUTHOR) |
| Source: | Journal of Antimicrobial Chemotherapy (JAC). Oct2019, Vol. 74 Issue 10, p3056-3062. 7p. |
| Database: | Environment Complete |
| ISSN: | 03057453 |
|---|---|
| DOI: | 10.1093/jac/dkz277 |
